MACROPHAGE BASED MELANOMA VACCINE

$19,111M01FY2000RRNIH

University Of Connecticut Sch Of Med/Dnt, Farmington CT

Investigators

Linked publications & trials

Paper 39277143 Paper 38684046 Paper 38225874 Paper 34914409 Paper 34553964 Paper 34014689 Paper 33373529 Paper 33138928 Paper 32574382 Paper 31436886 Paper 31343196 Paper 31318225 Paper 31018870 Paper 30862775 Paper 30557565 Paper 30470456 Paper 29554115 Paper 29428697 Paper 29156239 Paper 28905881 Paper 28176803 Paper 27915167 Paper 27784318 Paper 27633766 Paper 27354234 Paper 27196697 Paper 27020748 Paper 26828635 Paper 26399377 Paper 26375977 Paper 26250693 Paper 26237326 Paper 26184649 Paper 26167714 Paper 26143063 Paper 26098476 Paper 25953963 Paper 25895020 Paper 25531935 Paper 25507149 Paper 25458578 Paper 25436841 Paper 25417421 Paper 25413264 Paper 25245136 Paper 25198284 Paper 25182071 Paper 25151488 Paper 25135999 Paper 25070809 Paper 24955678 Paper 24865619 Paper 24838369 Paper 24786948 Paper 24663682 Paper 24655501 Paper 24628943 Paper 24592874 Paper 24557088 Paper 24522467 Paper 24489452 Paper 24392603 Paper 24349863 Paper 24267042 Paper 24215204 Paper 24183127 Paper 24179787 Paper 24166645 Paper 24128075 Paper 24121998 Paper 24094979 Paper 24057996 Paper 23951358 Paper 23935194 Paper 23895570 Paper 23873776 Paper 23766429 Paper 23674177 Paper 23631869 Paper 23586451 Paper 23545499 Paper 23528194 Paper 23504203 Paper 23453090 Paper 23414496 Paper 23398227 Paper 23394688 Paper 23387883 Paper 23379736 Paper 23299384 Paper 23266101 Paper 23254227 Paper 23239122 Paper 23145795 Paper 23057044 Paper 23033146 Paper 23011382 Paper 22962001 Paper 22882390 Paper 22793522

Abstract

The major goal of this project has been to undertake a critical evaluation of the immunogenic potential of synthetic peptide or melanoma cell lysate loaded APC. Thirty patients have thus far been treated. There has been no reportable toxicity and no therapy-related deaths. Clinical and immunologic evaluations suggest that the approach is clearly feasible and that the vaccines have biological activities. The grant has been renewed by the NIH. This renewal also has a clinical trial component with a revised protocol. As such, the basic work will be continued. We plan to enter approximately 18-24 patients over the next three years. Our major scientific finding is that the vaccine is capable of inducing a CD8+ CTL type response, in situ, at the vaccine site, at tumor deposits, and in the circulation.

View original record on NIH RePORTER →